Skip to main content
Erschienen in: American Journal of Clinical Dermatology 4/2020

09.12.2019 | Original Research Article

Neurological Cancer is a Risk Factor for Bullous Pemphigoid: 11-Year Population-Based Cohort Study

verfasst von: Chen-Yi Wu, Hsiao-Yun Hu, Yiing-Jenq Chou, Chung-Pin Li, Yun-Ting Chang

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

There is evidence suggesting an association between bullous pemphigoid (BP) and a range of neurological diseases. Whether neurological cancer is a risk factor for BP remains unknown.

Objective

The aim of the study was to investigate the risk of subsequent BP among patients with neurological cancer.

Methods

This nationwide population-based cohort study was based on data obtained from the Taiwan National Health Insurance Research Database between 2000 and 2012. A total of 8313 patients with neurological cancer and 33,252 age-, sex-, and index-date-matched controls were recruited. The hazard ratio (HR) for subsequent BP in patients with neurological cancer was analyzed using a Cox model and Fine-Gray competing risk model, with mortality as the competing event.

Results

The incidence rates of BP per 100,000 person-years were 37.2 for patients with neurological cancer and 6.8 for controls. The crude incidence rate ratio was 5.49 (95% confidence interval [CI] 2.18–13.30). The mean time to occurrence of BP was 4.48 ± 3.40 years for patients with neurological cancer. Neurological cancer (HR 9.65, 95% CI 3.76–24.77 for the Cox model; HR 2.41, 95% CI 1.14–5.14 for the competing risk model), age per year (HR 1.10, 95% CI 1.05–1.15 for the Cox model; HR 1.06, 95% CI 1.02–1.09 for the competing risk model), and dementia (HR 6.31, 95% CI 2.49–15.99 for the Cox model; HR 7.50, 95% CI 2.84–19.85 for the competing risk model) significantly increased the risk of BP.

Conclusions

Neurological cancer increased the risk for subsequent BP by 2.4-fold, with a relatively short gap of 4.5 years.
Literatur
1.
Zurück zum Zitat Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–32.PubMed Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–32.PubMed
2.
Zurück zum Zitat Marazza G, Pham HC, Scharer L, Pedrazzetti PP, Hunziker T, Trueb RM, Hohl D, Itin P, Lautenschlager S, Naldi L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009;161(4):861–8.PubMed Marazza G, Pham HC, Scharer L, Pedrazzetti PP, Hunziker T, Trueb RM, Hohl D, Itin P, Lautenschlager S, Naldi L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009;161(4):861–8.PubMed
3.
Zurück zum Zitat Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266–8.PubMed Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266–8.PubMed
4.
Zurück zum Zitat Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.PubMed Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.PubMed
5.
Zurück zum Zitat Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ, Al-Hashimi M, Wieland CN. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71(1):92–9.PubMedPubMedCentral Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ, Al-Hashimi M, Wieland CN. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71(1):92–9.PubMedPubMedCentral
6.
Zurück zum Zitat Hubner F, Recke A, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Investig Dermatol. 2016;136(12):2495–8.PubMed Hubner F, Recke A, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Investig Dermatol. 2016;136(12):2495–8.PubMed
7.
Zurück zum Zitat Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, Courville P, Bravard P, Remond B, Doffoel-Hantz V, et al. Incidence and mortality of bullous pemphigoid in France. J Investig Dermatol. 2012;132(8):1998–2004.PubMed Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, Courville P, Bravard P, Remond B, Doffoel-Hantz V, et al. Incidence and mortality of bullous pemphigoid in France. J Investig Dermatol. 2012;132(8):1998–2004.PubMed
8.
Zurück zum Zitat Thorslund K, Seifert O, Nilzen K, Gronhagen C. Incidence of bullous pemphigoid in Sweden 2005–2012: a nationwide population-based cohort study of 3761 patients. Arch Dermatol Res. 2017;309(9):721–7.PubMedPubMedCentral Thorslund K, Seifert O, Nilzen K, Gronhagen C. Incidence of bullous pemphigoid in Sweden 2005–2012: a nationwide population-based cohort study of 3761 patients. Arch Dermatol Res. 2017;309(9):721–7.PubMedPubMedCentral
9.
Zurück zum Zitat Goletz S, Zillikens D, Schmidt E. Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. Exp Dermatol. 2017;26(12):1154–62.PubMed Goletz S, Zillikens D, Schmidt E. Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. Exp Dermatol. 2017;26(12):1154–62.PubMed
10.
Zurück zum Zitat Stanley JR. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol. 1993;53:291–325.PubMed Stanley JR. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol. 1993;53:291–325.PubMed
11.
Zurück zum Zitat Brick KE, Weaver CH, Savica R, Lohse CM, Pittelkow MR, Boeve BF, Gibson LE, Camilleri MJ, Wieland CN. A population-based study of the association between bullous pemphigoid and neurologic disorders. J Am Acad Dermatol. 2014;71(6):1191–7.PubMedPubMedCentral Brick KE, Weaver CH, Savica R, Lohse CM, Pittelkow MR, Boeve BF, Gibson LE, Camilleri MJ, Wieland CN. A population-based study of the association between bullous pemphigoid and neurologic disorders. J Am Acad Dermatol. 2014;71(6):1191–7.PubMedPubMedCentral
12.
Zurück zum Zitat Forsti AK, Jokelainen J, Ansakorpi H, Seppanen A, Majamaa K, Timonen M, Tasanen K. Psychiatric and neurological disorders are associated with bullous pemphigoid—a nationwide Finnish Care Register study. Sci Rep. 2016;6:37125.PubMedPubMedCentral Forsti AK, Jokelainen J, Ansakorpi H, Seppanen A, Majamaa K, Timonen M, Tasanen K. Psychiatric and neurological disorders are associated with bullous pemphigoid—a nationwide Finnish Care Register study. Sci Rep. 2016;6:37125.PubMedPubMedCentral
13.
Zurück zum Zitat Forsti AK, Huilaja L, Schmidt E, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol. 2017;26(12):1228–34.PubMed Forsti AK, Huilaja L, Schmidt E, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol. 2017;26(12):1228–34.PubMed
14.
Zurück zum Zitat Kibsgaard L, Rasmussen M, Lamberg A, Deleuran M, Olesen AB, Vestergaard C. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol. 2017;176(6):1486–91.PubMed Kibsgaard L, Rasmussen M, Lamberg A, Deleuran M, Olesen AB, Vestergaard C. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol. 2017;176(6):1486–91.PubMed
15.
Zurück zum Zitat Papakonstantinou E, Limberg MM, Gehring M, Kotnik N, Kapp A, Gibbs BF, Raap U. Neurological disorders are associated with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2019;33(5):925–9.PubMed Papakonstantinou E, Limberg MM, Gehring M, Kotnik N, Kapp A, Gibbs BF, Raap U. Neurological disorders are associated with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2019;33(5):925–9.PubMed
16.
Zurück zum Zitat Pankakoski A, Sintonen H, Ranki A, Kluger N. Comorbidities of bullous pemphigoid in a Finnish cohort. Eur J Dermatol. 2018;28(2):157–61.PubMed Pankakoski A, Sintonen H, Ranki A, Kluger N. Comorbidities of bullous pemphigoid in a Finnish cohort. Eur J Dermatol. 2018;28(2):157–61.PubMed
17.
Zurück zum Zitat Kokkonen N, Herukka SK, Huilaja L, Kokki M, Koivisto AM, Hartikainen P, Remes AM, Tasanen K. Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer’s disease. J Investig Dermatol. 2017;137(1):71–6.PubMed Kokkonen N, Herukka SK, Huilaja L, Kokki M, Koivisto AM, Hartikainen P, Remes AM, Tasanen K. Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer’s disease. J Investig Dermatol. 2017;137(1):71–6.PubMed
18.
Zurück zum Zitat Li L, Chen J, Wang B, Yao Y, Zuo Y. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol. 2009;160(6):1343–5.PubMed Li L, Chen J, Wang B, Yao Y, Zuo Y. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol. 2009;160(6):1343–5.PubMed
19.
Zurück zum Zitat Chen J, Li L, Chen J, Zeng Y, Xu H, Song Y, Wang B. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology. 2011;57(3):211–6.PubMed Chen J, Li L, Chen J, Zeng Y, Xu H, Song Y, Wang B. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology. 2011;57(3):211–6.PubMed
20.
Zurück zum Zitat Seppanen A, Suuronen T, Hofmann SC, Majamaa K, Alafuzoff I. Distribution of collagen XVII in the human brain. Brain Res. 2007;1158:50–6.PubMed Seppanen A, Suuronen T, Hofmann SC, Majamaa K, Alafuzoff I. Distribution of collagen XVII in the human brain. Brain Res. 2007;1158:50–6.PubMed
21.
Zurück zum Zitat Kunzli K, Favre B, Chofflon M, Borradori L. One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1. Exp Dermatol. 2016;25(1):10–6.PubMed Kunzli K, Favre B, Chofflon M, Borradori L. One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1. Exp Dermatol. 2016;25(1):10–6.PubMed
22.
Zurück zum Zitat Chen CT, Hu HY, Chang YT, Li CP, Wu CY. Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study. Br J Dermatol. 2019;180(3):553–8.PubMed Chen CT, Hu HY, Chang YT, Li CP, Wu CY. Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study. Br J Dermatol. 2019;180(3):553–8.PubMed
23.
Zurück zum Zitat Dai YX, Wang SC, Chou YJ, Chang YT, Chen TJ, Li CP, Wu CY. Smoking, but not alcohol, is associated with risk of psoriasis in a Taiwanese population-based cohort study. J Am Acad Dermatol. 2019;80(3):727–34.PubMed Dai YX, Wang SC, Chou YJ, Chang YT, Chen TJ, Li CP, Wu CY. Smoking, but not alcohol, is associated with risk of psoriasis in a Taiwanese population-based cohort study. J Am Acad Dermatol. 2019;80(3):727–34.PubMed
24.
Zurück zum Zitat Wu CY, Hu HY, Li CP, Chou YJ, Chang YT. Comorbidity profiles of psoriasis in Taiwan: a latent class analysis. PLoS One. 2018;13(2):e0192537.PubMedPubMedCentral Wu CY, Hu HY, Li CP, Chou YJ, Chang YT. Comorbidity profiles of psoriasis in Taiwan: a latent class analysis. PLoS One. 2018;13(2):e0192537.PubMedPubMedCentral
25.
Zurück zum Zitat Hou YC, Hu HY, Liu IL, Chang YT, Wu CY. The risk of autoimmune connective tissue diseases in patients with atopy: a nationwide population-based cohort study. Allergy Asthma Proc. 2017;38(5):383–9.PubMed Hou YC, Hu HY, Liu IL, Chang YT, Wu CY. The risk of autoimmune connective tissue diseases in patients with atopy: a nationwide population-based cohort study. Allergy Asthma Proc. 2017;38(5):383–9.PubMed
26.
Zurück zum Zitat Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244–56.PubMedPubMedCentral Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244–56.PubMedPubMedCentral
27.
Zurück zum Zitat de Glas NA, Kiderlen M, Vandenbroucke JP, de Craen AJ, Portielje JE, van de Velde CJ, Liefers GJ, Bastiaannet E, Le Cessie S. Performing survival analyses in the presence of competing risks: a clinical example in older breast cancer patients. J Natl Cancer Inst. 2016;108(5):djv366.PubMed de Glas NA, Kiderlen M, Vandenbroucke JP, de Craen AJ, Portielje JE, van de Velde CJ, Liefers GJ, Bastiaannet E, Le Cessie S. Performing survival analyses in the presence of competing risks: a clinical example in older breast cancer patients. J Natl Cancer Inst. 2016;108(5):djv366.PubMed
28.
Zurück zum Zitat Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391–400.PubMedPubMedCentral Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391–400.PubMedPubMedCentral
29.
Zurück zum Zitat Messingham KN, Miller AD, Narayanan NS, Connell SJ, Fairley JA. Demographics and autoantibody profiles of pemphigoid patients with underlying neurologic diseases. J Investig Dermatol. 2019;139(9):1860–6.PubMed Messingham KN, Miller AD, Narayanan NS, Connell SJ, Fairley JA. Demographics and autoantibody profiles of pemphigoid patients with underlying neurologic diseases. J Investig Dermatol. 2019;139(9):1860–6.PubMed
30.
Zurück zum Zitat Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, Hwang CY, Chu SY, Chen CC, Lee DD, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011;165(3):593–9.PubMed Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, Hwang CY, Chu SY, Chen CC, Lee DD, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011;165(3):593–9.PubMed
31.
Zurück zum Zitat Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30(12):2007–15.PubMed Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30(12):2007–15.PubMed
32.
Zurück zum Zitat Seppanen A, Autio-Harmainen H, Alafuzoff I, Sarkioja T, Veijola J, Hurskainen T, Bruckner-Tuderman L, Tasanen K, Majamaa K. Collagen XVII is expressed in human CNS neurons. Matrix Biol. 2006;25(3):185–8.PubMed Seppanen A, Autio-Harmainen H, Alafuzoff I, Sarkioja T, Veijola J, Hurskainen T, Bruckner-Tuderman L, Tasanen K, Majamaa K. Collagen XVII is expressed in human CNS neurons. Matrix Biol. 2006;25(3):185–8.PubMed
33.
Zurück zum Zitat Laffitte E, Burkhard PR, Fontao L, Jaunin F, Saurat JH, Chofflon M, Borradori L. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol. 2005;152(3):537–40.PubMed Laffitte E, Burkhard PR, Fontao L, Jaunin F, Saurat JH, Chofflon M, Borradori L. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol. 2005;152(3):537–40.PubMed
34.
Zurück zum Zitat Taghipour K, Chi CC, Bhogal B, Groves RW, Venning V, Wojnarowska F. Immunopathological characteristics of patients with bullous pemphigoid and neurological disease. J Eur Acad Dermatol Venereol. 2014;28(5):569–73.PubMed Taghipour K, Chi CC, Bhogal B, Groves RW, Venning V, Wojnarowska F. Immunopathological characteristics of patients with bullous pemphigoid and neurological disease. J Eur Acad Dermatol Venereol. 2014;28(5):569–73.PubMed
35.
Zurück zum Zitat Seppanen A. Collagen XVII: a shared antigen in neurodermatological interactions? Clin Dev Immunol. 2013;2013:240570.PubMedPubMedCentral Seppanen A. Collagen XVII: a shared antigen in neurodermatological interactions? Clin Dev Immunol. 2013;2013:240570.PubMedPubMedCentral
36.
Zurück zum Zitat Messingham KN, Randall G, Fairley J. Exploring mechanisms of IgE-mediated autoimmunity through the lens of bullous pemphigoid. G Ital Dermatol Venereol. 2016;151(2):186–97.PubMed Messingham KN, Randall G, Fairley J. Exploring mechanisms of IgE-mediated autoimmunity through the lens of bullous pemphigoid. G Ital Dermatol Venereol. 2016;151(2):186–97.PubMed
Metadaten
Titel
Neurological Cancer is a Risk Factor for Bullous Pemphigoid: 11-Year Population-Based Cohort Study
verfasst von
Chen-Yi Wu
Hsiao-Yun Hu
Yiing-Jenq Chou
Chung-Pin Li
Yun-Ting Chang
Publikationsdatum
09.12.2019
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 4/2020
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-019-00494-y

Weitere Artikel der Ausgabe 4/2020

American Journal of Clinical Dermatology 4/2020 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.